Vertex Pharmaceuticals Net Change in Cash and Restricted Cash remained flat by 0.0% to $128.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 108.9%, from -$1.45B to $128.90M. Over 2 years (FY 2023 to FY 2025), Net Change in Cash and Restricted Cash shows an upward trend with a 92.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive value indicates an increase in liquidity, while a negative value indicates a decrease in cash reserves.
This metric measures the total net movement in cash, cash equivalents, and restricted cash balances over a specific repo...
Commonly found in the reconciliation of cash and cash equivalents in the statement of cash flows.
is_cvx_net_change_in_cash_and_restricted_cash| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$139.70M | -$5.80B | $515.60M |
| YoY Change | — | <-999% | +108.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.